<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In contrast to previous International Psychogeriatric Association (<z:chebi fb="23" ids="17824,30802">IPA</z:chebi>) meetings, there was a preponderance of sessions dedicated to pharmacological management of <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> due to <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), especially by <z:chebi fb="0" ids="37733">cholinesterase inhibitors</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="53289,53290,53292">Donepezil</z:chebi> (Eisai Co Ltd) and rivastigmine (Novartis AG) were most frequently featured, while propentofylline (Hoechst AG) has emerged as an agent potentially efficacious in both AD and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>A second focus was the treatment of the behavioral and psychological symptoms of <z:hpo ids='HP_0000726'>dementia</z:hpo> (BPSD), particularly by the atypical <z:chebi fb="0" ids="35476">antipsychotics</z:chebi> <z:chebi fb="0" ids="8871">risperidone</z:chebi> (Janssen Pharmaceutica NV), <z:chebi fb="0" ids="7735">olanzapine</z:chebi> (Eli Lilly &amp; Co) and <z:chebi fb="0" ids="8707">quetiapine</z:chebi> (AstraZeneca plc), but also by <z:chebi fb="0" ids="35623">anticonvulsants</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Some attempts were made to redress the balance by examining non-pharmacological treatments </plain></SENT>
<SENT sid="4" pm="."><plain>There were surprisingly few presentations on the management of <z:hpo ids='HP_0000716'>depression</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Fortunately, most of the presentations focused on the difficult issue of comorbid <z:hpo ids='HP_0000716'>depression</z:hpo> and medical illness </plain></SENT>
<SENT sid="6" pm="."><plain>Overall, there were no major disclosures of new drugs </plain></SENT>
<SENT sid="7" pm="."><plain>Most new data was simply a refinement of previously published material </plain></SENT>
</text></document>